Glenmark Secures Global Rights to Third-Generation EGFR-TKI Aumolertinib for Lung Cancer Treatment
核心洞察
Glenmark Specialty S.A. has signed an exclusive licensing agreement with Jiangsu Hansoh Pharmaceutical Group (搜索) for Aumolertinib (搜索), a third-generation EGFR (搜索)-TKI designed to treat non-small cell lung cancer.
The partnership grants Glenmark development and commercialization rights across multiple regions including the Middle East, Africa, Southeast Asia, Australia, New Zealand, and Russia/CIS.
Hansoh Pharma will receive an upfront payment in the low double-digit millions with potential milestone payments and royalties that could eventually exceed $1 billion.
Glenmark Pharmaceuticals has announced a strategic collaboration with China's Jiangsu Hansoh Pharmaceutical Group (搜索) to expand global access to Aumolertinib (搜索), a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR (搜索)-TKI) for treating non-small cell lung cancer (NSCLC).
Partnership Details and Financial Terms
Under the exclusive licensing and distribution agreement, Glenmark Specialty S.A. (GSSA), a subsidiary of Glenmark Pharmaceuticals, has secured development and commercialization rights for Aumolertinib (搜索) across several key regions, including the Middle East, Africa, Southeast and South Asia, Australia, New Zealand, and Russia/CIS.
The financial structure includes an upfront payment to Hansoh Pharma in the low double-digit millions, with potential milestone payments and royalties that could eventually exceed $1 billion. This substantial investment reflects the significant commercial potential of the therapy in the designated markets.
Drug Profile and Regulatory Status
Aumolertinib (搜索), marketed as Ameile in China and Aumseqa in the United Kingdom and Europe, represents a significant advancement in EGFR (搜索)-targeted therapy. The drug has received marketing authorization from the UK MHRA as a monotherapy and is indicated for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR mutations, as well as for the treatment of adult patients with locally advanced or metastatic EGFR T790M (搜索) mutation-positive NSCLC.
In China, Aumolertinib (搜索) has achieved approval for four distinct indications: second-line T790M (搜索) mutation, first-line NSCLC EGFR (搜索) mutated, unresectable Stage III post-chemoradiotherapy, and adjuvant Stage II-IIIB NSCLC. This broad approval profile demonstrates the drug's versatility across different stages and treatment settings of lung cancer.
Strategic Significance
"At Glenmark, we remain focused on building a growth-oriented oncology business across high-potential markets. Aumolertinib (搜索) is a strategic addition that strengthens our near-term commercial pipeline and enhances our ability to serve patients with EGFR (搜索)-mutated lung cancer," said Glenn Saldanha, Chairman and Managing Director of Glenmark Pharmaceuticals Ltd. "This collaboration reinforces our disciplined approach to expanding our innovative portfolio and widening access to advanced cancer care across key markets."
The partnership represents a milestone for both companies, as Aumolertinib (搜索) became Hansoh Pharma's first innovative drug approved in an overseas market and the first China-developed EGFR (搜索)-TKI to be launched internationally. This achievement underscores the growing capabilities of Chinese pharmaceutical companies in developing globally competitive oncology treatments.
Market Expansion Strategy
The collaboration aligns with Glenmark's strategic expansion of their innovative cancer treatment portfolio. By securing rights to this cutting-edge therapy, Glenmark positions itself to address the significant unmet medical needs of patients with EGFR (搜索)-mutated lung cancer across diverse international markets that have historically had limited access to advanced targeted therapies.